These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 30102618)

  • 41. Effect of abatacept on the immunogenicity of 23-valent pneumococcal polysaccharide vaccination (PPSV23) in rheumatoid arthritis patients.
    Migita K; Akeda Y; Akazawa M; Tohma S; Hirano F; Ideguchi H; Kozuru H; Jiuchi Y; Matsumura R; Suematsu E; Miyamura T; Mori S; Fukui T; Izumi Y; Iwanaga N; Tsutani H; Saisyo K; Yamanaka T; Ohshima S; Mori N; Matsumori A; Takahi K; Yoshizawa S; Kawabe Y; Suenaga Y; Ozawa T; Hamada N; Komiya Y; Matsui T; Furukawa H; Oishi K
    Arthritis Res Ther; 2015 Dec; 17():357. PubMed ID: 26653668
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Studies of the mechanism of nephrotoxicity of compound A in rats.
    Martin JL; Kandel L; Laster MJ; Kerschmann RL; Eger EI
    J Anesth; 1997 Mar; 11(1):32-37. PubMed ID: 28921267
    [TBL] [Abstract][Full Text] [Related]  

  • 43. ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms.
    Kuroda J; Kimura S; Andreeff M; Ashihara E; Kamitsuji Y; Yokota A; Kawata E; Takeuchi M; Tanaka R; Murotani Y; Matsumoto Y; Tanaka H; Strasser A; Taniwaki M; Maekawa T
    Br J Haematol; 2008 Jan; 140(2):181-90. PubMed ID: 18028486
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification.
    Wang J; Goetsch L; Tucker L; Zhang Q; Gonzalez A; Vaidya KS; Oleksijew A; Boghaert E; Song M; Sokolova I; Pestova E; Anderson M; Pappano WN; Ansell P; Bhathena A; Naumovski L; Corvaia N; Reilly EB
    BMC Cancer; 2016 Feb; 16():105. PubMed ID: 26879245
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Development of an asymmetric Michael addition in a practical synthesis of ABT-546.
    Barnes DM
    Curr Opin Drug Discov Devel; 2000 Nov; 3(6):818-24. PubMed ID: 19649909
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In Vitro and In Vivo Mechanistic Studies toward Understanding the Role of 1-Aminobenzotriazole in Rat Drug-Drug Interactions.
    Boily MO; Chauret N; Laterreur J; Leblond FA; Boudreau C; Duquet MC; Lévesque JF; Ste-Marie L; Pichette V
    Drug Metab Dispos; 2015 Dec; 43(12):1960-5. PubMed ID: 26438628
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction.
    Kumar GN; Dykstra J; Roberts EM; Jayanti VK; Hickman D; Uchic J; Yao Y; Surber B; Thomas S; Granneman GR
    Drug Metab Dispos; 1999 Aug; 27(8):902-8. PubMed ID: 10421617
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of ketoconazole on the pharmacokinetics of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor ABT-384 and its two active metabolites in healthy volunteers: population analysis of data from a drug-drug interaction study.
    An G; Liu W; Katz DA; Marek G; Awni W; Dutta S
    Drug Metab Dispos; 2013 May; 41(5):1035-45. PubMed ID: 23431112
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Thrombospondin peptide ABT-898 inhibits inflammation and angiogenesis in a colitis model.
    Gutierrez LS; Ling J; Nye D; Papathomas K; Dickinson C
    World J Gastroenterol; 2015 May; 21(20):6157-66. PubMed ID: 26034351
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Simultaneous orbital decompression and correction of upper eyelid retraction versus staged procedures in thyroid-related orbitopathy.
    Ben Simon GJ; Mansury AM; Schwarcz RM; Lee S; McCann JD; Goldberg RA
    Ophthalmology; 2005 May; 112(5):923-32. PubMed ID: 15878077
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107.
    Malysz J; Anderson DJ; Grønlien JH; Ji J; Bunnelle WH; Håkerud M; Thorin-Hagene K; Ween H; Helfrich R; Hu M; Gubbins E; Gopalakrishnan S; Puttfarcken PS; Briggs CA; Li J; Meyer MD; Dyhring T; Ahring PK; Nielsen EØ; Peters D; Timmermann DB; Gopalakrishnan M
    J Pharmacol Exp Ther; 2010 Sep; 334(3):863-74. PubMed ID: 20504915
    [TBL] [Abstract][Full Text] [Related]  

  • 52. (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: I. In vitro characterization.
    Arneric SP; Sullivan JP; Briggs CA; Donnelly-Roberts D; Anderson DJ; Raszkiewicz JL; Hughes ML; Cadman ED; Adams P; Garvey DS
    J Pharmacol Exp Ther; 1994 Jul; 270(1):310-8. PubMed ID: 7518514
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Characterization of [3H]ABT-418: a novel cholinergic channel ligand.
    Anderson DJ; Williams M; Pauly JR; Raszkiewicz JL; Campbell JE; Rotert G; Surber B; Thomas SB; Wasicak J; Arneric SP
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1434-41. PubMed ID: 7791118
    [TBL] [Abstract][Full Text] [Related]  

  • 54. (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization.
    Decker MW; Brioni JD; Sullivan JP; Buckley MJ; Radek RJ; Raszkiewicz JL; Kang CH; Kim DJ; Giardina WJ; Wasicak JT
    J Pharmacol Exp Ther; 1994 Jul; 270(1):319-28. PubMed ID: 7913497
    [TBL] [Abstract][Full Text] [Related]  

  • 55. ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective antinociceptive agent acting via neuronal nicotinic acetylcholine receptors: II. In vivo characterization.
    Bannon AW; Decker MW; Curzon P; Buckley MJ; Kim DJ; Radek RJ; Lynch JK; Wasicak JT; Lin NH; Arnold WH; Holladay MW; Williams M; Arneric SP
    J Pharmacol Exp Ther; 1998 May; 285(2):787-94. PubMed ID: 9580627
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetic and Immunological Considerations for Expanding the Therapeutic Window of Next-Generation Antibody-Drug Conjugates.
    Khera E; Thurber GM
    BioDrugs; 2018 Oct; 32(5):465-480. PubMed ID: 30132210
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma.
    Phillips T; Barr PM; Park SI; Kolibaba K; Caimi PF; Chhabra S; Kingsley EC; Boyd T; Chen R; Carret AS; Gartner EM; Li H; Yu C; Smith DC
    Invest New Drugs; 2019 Apr; 37(2):297-306. PubMed ID: 30132271
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Activating Autophagy Enhanced the Antitumor Effect of Antibody Drug Conjugates Rituximab-Monomethyl Auristatin E.
    Wang Y; Zhang X; Fan J; Chen W; Luan J; Nan Y; Wang S; Chen Q; Zhang Y; Wu Y; Ju D
    Front Immunol; 2018; 9():1799. PubMed ID: 30123222
    [TBL] [Abstract][Full Text] [Related]  

  • 59. SLC46A3 as a Potential Predictive Biomarker for Antibody-Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads.
    Kinneer K; Meekin J; Tiberghien AC; Tai YT; Phipps S; Kiefer CM; Rebelatto MC; Dimasi N; Moriarty A; Papadopoulos KP; Sridhar S; Gregson SJ; Wick MJ; Masterson L; Anderson KC; Herbst R; Howard PW; Tice DA
    Clin Cancer Res; 2018 Dec; 24(24):6570-6582. PubMed ID: 30131388
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate.
    Brand C; Sadique A; Houghton JL; Gangangari K; Ponte JF; Lewis JS; Pillarsetty NVK; Konner JA; Reiner T
    EJNMMI Res; 2018 Aug; 8(1):87. PubMed ID: 30155674
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.